Daniel Carestio Sells 1,374 Shares of STERIS (NYSE:STE) Stock

STERIS plc (NYSE:STE) CEO Daniel Carestio sold 1,374 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $212.00, for a total value of $291,288.00. Following the completion of the transaction, the chief executive officer directly owned 63,647 shares of the company’s stock, valued at approximately $13,493,164. This trade represents a 2.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

STERIS Price Performance

Shares of NYSE STE traded down $2.16 during mid-day trading on Monday, reaching $210.19. The company’s stock had a trading volume of 658,842 shares, compared to its average volume of 798,173. The firm has a market capitalization of $20.51 billion, a PE ratio of 26.51 and a beta of 0.93. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The stock has a fifty day moving average of $217.24 and a two-hundred day moving average of $238.96. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44.

STERIS (NYSE:STE) last released its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.59 billion. STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business’s revenue was up 6.7% on a year-over-year basis. During the same period last year, the company earned $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, sell-side analysts anticipate that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 26th. Stockholders of record on Monday, June 8th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.2%. STERIS’s dividend payout ratio is 31.78%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Piper Sandler reissued an “overweight” rating and set a $270.00 price target on shares of STERIS in a research note on Thursday, May 21st. KeyCorp dropped their price target on STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Finally, Weiss Ratings lowered STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, STERIS presently has an average rating of “Moderate Buy” and an average target price of $278.00.

Hedge Funds Weigh In On STERIS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STE. Norges Bank bought a new stake in shares of STERIS in the 4th quarter valued at approximately $320,298,000. AQR Capital Management LLC lifted its stake in shares of STERIS by 178.6% in the 3rd quarter. AQR Capital Management LLC now owns 1,183,070 shares of the medical equipment provider’s stock valued at $291,704,000 after purchasing an additional 758,423 shares during the last quarter. Boston Partners bought a new stake in shares of STERIS in the 3rd quarter valued at approximately $158,982,000. Orbis Allan Gray Ltd lifted its stake in shares of STERIS by 36.0% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,100,099 shares of the medical equipment provider’s stock valued at $504,486,000 after purchasing an additional 556,088 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its stake in shares of STERIS by 25.7% in the 1st quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock valued at $411,995,000 after purchasing an additional 380,504 shares during the last quarter. 94.69% of the stock is owned by institutional investors.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.